Cargando…
Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using (111)In-bevacizumab
BACKGROUND: The ability to image vascular endothelial growth factor (VEGF) could enable prospective, non-invasive monitoring of patients receiving anti-angiogenic therapy. This study investigates the specificity and pharmacokinetics of (111)In-bevacizumab binding to VEGF and its use for assessing re...
Autores principales: | Patel, Neel, Able, Sarah, Allen, Danny, Fokas, Emmanouil, Cornelissen, Bart, Gleeson, Fergus V., Harris, Adrian L., Vallis, Katherine A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5449352/ https://www.ncbi.nlm.nih.gov/pubmed/28560583 http://dx.doi.org/10.1186/s13550-017-0297-9 |
Ejemplares similares
-
Accumulation of (111)In-Labelled EGF-Au-PEG Nanoparticles in EGFR-Positive Tumours is Enhanced by Coadministration of Targeting Ligand
por: Song, Lei, et al.
Publicado: (2017) -
(111)In-BnDTPA-F3: an Auger electron-emitting radiotherapeutic agent that targets nucleolin
por: Cornelissen, Bart, et al.
Publicado: (2012) -
Methylnaltrexone Potentiates the Anti-Angiogenic Effects of mTOR Inhibitors
por: Singleton, Patrick A, et al.
Publicado: (2010) -
Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling
por: Allen, Elizabeth, et al.
Publicado: (2016) -
Regulation of O(2) consumption by the PI3K and mTOR pathways contributes to tumor hypoxia
por: Kelly, Catherine J., et al.
Publicado: (2014)